Available Trials

Advanced/Metastatic Malignancies

  • USO 16041

    An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies Investigational Product(s), Dose and Mode of Administration, Duration of Treatment with Investigational

    Available at 6 locations

Breast Cancer

  • USO 11025 (STAR TRIAL)

    A Phase II Multicenter Single-arm Study of BKM120 plus Capecitabine for Breast Cancer Patients with Brain Metastasis.

    Available at 6 locations

  • USO 15130

    A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

    Available at 6 locations

  • USO 13033

    A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer with histologic confirmation: ER+, HER2- invasive breast cancer (any PgR status) or poorly differentiated and/or invasive TNBC as defined by HER2-, ER-/PR- status, with Measurable disease by RECIST 1.1, or non measurable lytic, bone-only disease. Cannot have more than 1 chemo in metastatic setting.

    Available at 6 locations

Gastric

  • GASTRIC USO 15089

    A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

    Available at 6 locations

Hematologic

  • Large B-CELL Lymphoma

    ROBUST trial – Phase III Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects with Previously Untreated, Non-Germinal Center Type Diffuse Large B-cell Lymphoma

    Available at 6 locations

  • MDS/AML OBSERVATIONAL STUDY

    Connect MDS and AML Disease registry

    Available at 6 locations

  • CLL UNITY trial

    A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia.

    Available at 6 locations

  • CLL – ACE-CL-006

    A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

    Available at 6 locations

Lung Cancer

  • LUNG USO 16156

    A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with NSCLC

    Available at 6 locations

  • LUNG GO29438

    A phase 3, open-label, randomized study of Atezolizumab (mpdl3280a, anti−pd-l1 antibody) in combination with carboplatin or cisplatin + pemetrexed compared with carboplatin or cisplatin + pemetrexed in patients who are chemotherapy-naive and have stage IV non-squamous NSCLC

    Available at 6 locations

  • Genentech GO29527

    A Phase III, Open label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PDL1 Antibody) Compared With Standard of Care Following Adjuvant Cisplatin-based Chemotherapy in PDL-1 Selected Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer

    Available at 6 locations

  • USO 14158

    CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

    Available at 6 locations

  • USO 13172

    Observational/non-interventional study for metastatic NSCLC AND EXTENSIVE DISEASE SCLC

    Available at 6 locations

  • USO 15014

    GO29437: A phase ill, open-label, multicenter, randomized study evaluating the efficacy and safety of mpdl3280a (anti-pd-l1 antibody) in combination with carboplatin + paclitaxel or mpdl3280a in combination with carboplatin +nab-paclitaxel versus carboplatin + nab-paclitaxel in chemotherapy naive patients with stage iv squamous non-small cell lung cancer

    Available at 6 locations

  • USO 15013

    (GO29436) a phase iii, open-label, randomized study of mpdl3280a (anti−pd-l1 antibody) in combination with carboplatin + paclitaxel with or without bevacizumab compared with carboplatin + paclitaxel + bevacizumab in chemotherapy-naïve patients with stage iv non-squamous non−small cell lung cancer

    Available at 6 locations

Lymphoma

  • LYMPHOMA USO 16065

    A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma (UTX-TGR-205)

    Available at 6 locations

Multiple Myeloma

  • MULTIPLE MYELOMA USO 16084

    Daratumumab plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD)in Previously Untreated and Relapsed Subjects with Multiple Myeloma

    Available at 6 locations

  • MULTIPLE MYELOMA USO 16035

    global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT-MM study – start Nov2016

    Available at 6 locations

Ovarian

  • OVARIAN USO 15236

    A phase 3, multicenter, randomized, open-label study of avelumab* (msb0010718c) alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer (B9991009)

    Available at 5 locations

  • OVARIAN USO 15236

    A phase 3, multicenter, randomized, open-label study of avelumab* (msb0010718c) alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer (B9991009)

    Available at 6 locations

Prostate Cancer

  • PROSTATE USO 16159

    A Phase III, Multicenter, Randomized Study Of Atezolizumab (Anti−Pd-L1 Antibody) In Combination With Enzalutamide Versus Enzalutamide Alone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of An Androgen Synthesis inhibitor And Failure Of, Ineligibility For, Or Refusal Of A Taxane Regimen

    Available at 6 locations

Supportive

  • USO 15026

    Efficacy and Safety of Rivaroxaban Prophlaxis Compared to Placebo in Ambulatory Cancer Patients at High Venous Thromboembolism Risk Undergoing Chemotherapy for Mixed Malignancies (39039039STM4001).

    Available at 6 locations